Clinical Trial Update: A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) [Phase 1, Phase 2]

View source ↗

Summary

This trial update covers a dose-finding Phase 1 study of sarilumab plus capecitabine in HER2-negative metastatic breast cancer and a Phase 2, historically contr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Sarilumab (sarilumab)

Snippet

Sponsor: University of Southern California | Conditions: Breast, Metastatic | Phase 1, Phase 2 | Status: RECRUITING